Literature DB >> 2729951

Pseudomonas cepacia susceptibility to sulbactam.

G A Jacoby1, L Sutton.   

Abstract

For 25 of 32 Pseudomonas cepacia isolates, predominantly from sputum of adult patients, agar dilution MICs of sulbactam were 2.5 micrograms/ml, and for only one was the MIC more than 80 micrograms/ml. Susceptibility was reliably predicted by response to a commercial sulbactam-ampicillin disk.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2729951      PMCID： PMC172485          DOI： 10.1128/AAC.33.4.583

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Subacute and acute endocarditis due to Pseudomonas cepacia in heroin addicts.

Authors:  E R Noriega; E Rubinstein; M S Simberkoff; J J Rahal
Journal:  Am J Med       Date:  1975-07       Impact factor: 4.965

2.  Pseudomonas cepacia pneumonia.

Authors:  A J Weinstein; R C Moellering; C C Hopkins; A Goldblatt
Journal:  Am J Med Sci       Date:  1973-06       Impact factor: 2.378

3.  Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

Authors:  J A Retsema; A R English; A Girard; J E Lynch; M Anderson; L Brennan; C Cimochowski; J Faiella; W Norcia; P Sawyer
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

4.  In vitro susceptibility of Pseudomanas cepacia and Pseudomonas maltophilia to trimethoprim and trimethoprim-sulfamethoxazole.

Authors:  M R Moody; W M Young
Journal:  Antimicrob Agents Chemother       Date:  1975-06       Impact factor: 5.191

5.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

Review 6.  Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology.

Authors:  D A Goldmann; J D Klinger
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

7.  Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.

Authors:  R Gold; E Jin; H Levison; A Isles; P C Fleming
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790
  7 in total
  5 in total

Review 1.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

2.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.

Authors:  S Bonacorsi; F Fitoussi; S Lhopital; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

4.  Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.

Authors:  O Ozyilkan; U Yalçintaş; S Başkan
Journal:  Korean J Intern Med       Date:  1999-07       Impact factor: 2.884

Review 5.  Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of Non-Essential Target Inhibitors: A Review.

Authors:  Giannamaria Annunziato
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.